Abstract 278P
Background
Radiotherapy is an effective treatment option for local control of prostate cancer, but its role in the treatment of oligometastatic prostate cancer (omPCa) remains unclear. This study aimed to investigate the potential survival benefit of full-coverage radiotherapy in patients with omPCa.
Methods
A retrospective analysis was conducted on patients with omPCa who received full-coverage radiotherapy between July 2012 and June 2022. Full-coverage radiotherapy was defined as radiotherapy to all lesions, including the primary site and metastatic lesions. Overall survival (OS) was the primary endpoint, and biochemical progression-free survival (bPFS) and radiological progression-free survival (rPFS) were the secondary endpoint. The Kaplan-Meier method was used to estimate univariate analysis, and the log-rank test was used to conduct multivariate analysis.
Results
A total of 33 patients, including 31 de novo oligometastatic hormone-sensitive prostate cancer (omHSPC) patients and 2 oligometastatic castration-resistant prostate cancer (omCRPC) patients, were enrolled in the study. The median follow-up was 38.8 months (range: 4.2–70.6 months). The survival rates at 2, 3, and 5 years were 100%, 95.7%, and 81.2%, respectively. The median bPFS was 58.9 months (95% CI: 47.7 - 70.1 months). The median rPFS is 55.3 months (95% CI: 39.9 -70.8 months). According to the univariate analysis, TURP prior to radiotherapy, presence of symptoms related to the lesions, and the pre-radiotherapy status of CRPC were associated with poorer survival. Multivariate analysis showed EBRT synchronized with ADT or chemotherapy (p=0.016), non-CRPC status before radiotherapy(p=0.000), and PSA levels more than 1 ng/ml before radiotherapy ( p=0.014) may be associated with longer rPFS. Both univariate and multivariate studies have demonstrated that the coexistence of lymph node and bone metastases is associated with a higher risk of biochemical recurrence (p=0.02). The occurrence of acute adverse reactions of Grade 3 or higher was not observed.
Conclusions
Full-coverage radiotherapy with an optimistic bPFS and rPFS may improve the OS of patients with oligometastatic prostate cancer. Further prospective studies are warranted to confirm the findings of this retrospective analysis.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Department of Radiation Oncology, Shanghai Changhai Hospital, the Naval Medical Universit.
Funding
The First Affiliated Hospital of Navy Medical University “234 Subject Climbing Program” (2019YPT004), the First Affiliated Hospital of Naval Medical University “Youth Development Program”(2021JCQNO3).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract
580P - Efficacy and safety of dacomitinib as first-line treatment for advanced non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor <italic>(EGFR)</italic> 21L858R mutation: A multicenter, ambispective, consecutive case-series study
Presenter: Shouzheng Wang
Session: Poster Display
Resources:
Abstract